Additionally, downregulation of MERTK expression or therapeutic blockade of GAS6 by Warfarin resulted in reduced disease burden and prolonged overall survival in a systemic myeloma mouse model [124]. The gene discussed is MERTK; the disease is plasma cell myeloma.